EpimAb Biotherapeutics Funding: $219M Raised, Series C
EpimAb Biotherapeutics is based in China. It has raised $219M in total funding. Latest round: Series C.
EpimAb Biotherapeutics funding overview
EpimAb Biotherapeutics is based in China. EpimAb Biotherapeutics has raised $219M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in March 2021. The round record for EpimAb Biotherapeutics runs through 2021; nothing later has been disclosed. Investors on record include Oriza Seed Capital, Decheng Capital, 3D Bioventures, Cventures, Adrian Cheng, Cormorant Asset Management and 9 others. 15 distinct backers are named across the disclosed rounds.
EpimAb Biotherapeutics at a glance
Total raised
$219M
Latest round
Series C
Latest round date
March 2021
Headquarters
China
Notable investors
Oriza Seed Capital, Decheng Capital, 3D Bioventures, Cventures, Adrian Cheng, Cormorant Asset Management, Hidragon Capital, Hony Capital
Frequently asked about EpimAb Biotherapeutics funding
How much has EpimAb Biotherapeutics raised?
EpimAb Biotherapeutics has raised $219M in total disclosed funding across the rounds on record.
Who has invested in EpimAb Biotherapeutics?
Oriza Seed Capital, Decheng Capital, 3D Bioventures, Cventures, Adrian Cheng, Cormorant Asset Management are named among the investors backing EpimAb Biotherapeutics.
What was the latest EpimAb Biotherapeutics funding round?
The most recent disclosed round is a Series C, announced in March 2021.
Where is EpimAb Biotherapeutics based?
EpimAb Biotherapeutics is based in China.
When did EpimAb Biotherapeutics last raise?
The last disclosed EpimAb Biotherapeutics round closed in March 2021 at Series C.
Round data for EpimAb Biotherapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in China and backer lists below.
